Description:
FORM 9 - RECURRENCE AND CONTRALATERAL BREAST CANCER REPORT Quality Of Life Companion Study For JMA27 (NCIC-MA.27): A Randomized Phase III Trial Of Exemestane Versus Anastrozole With Or Without Celecoxib In Postmenopausal Women With Receptor Positive Primary Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=ABE31B86-C179-5457-E034-0003BA12F5E7
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=ABE31B86-C179-5457-E034-0003BA12F5E7Keywords:
Versions (3)
- 8/26/12 8/26/12 -
- 1/9/15 1/9/15 - Martin Dugas
- 9/20/21 9/20/21 -
Uploaded on:
September 20, 2021
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Breast Cancer NCT00090974 Follow-Up - FORM 9 - RECURRENCE AND CONTRALATERAL BREAST CANCER REPORT - 2058833v3.0
Submit within 6 weeks of the date of diagnosis.
- StudyEvent: FORM 9 - RECURRENCE AND CONTRALATERAL BREAST CANCER REPORT